Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 10/20 | 0.47 |
| ▸ | KDR | P35968 | 10/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18967932 | 0.83 | FLT1 (0.52) | FLT1KDRPLAUPLGMAOB | |
| SCHEMBL18952014 | 0.82 | FLT1 (0.44) | FLT1KDRPLAUPLGMAOB | |
| SCHEMBL18939136 | 0.81 | PLAU (0.67) | FLT1KDRPLAUPLGF2 | |
| SCHEMBL18968057 | 0.81 | RECQL (0.39) | FLT1KDRHDAC2HDAC6 | |
| SCHEMBL18952046 | 0.81 | PLAU (0.49) | FLT1KDRPLAUPLGHDAC1 | |
| Hydrochloric Acid SCHEMBL18939038 | 0.80 | PLAU (0.48) | FLT1KDRPLAUPLGHDAC1 | |
| SCHEMBL18967494 | 0.79 | PLAU (0.40) | KDRPLAUPLGF2F10 | |
| SCHEMBL30167818 | 0.77 | FLT1 (0.64) | FLT1KDRMAOBHDAC1HDAC2 | |
| SCHEMBL18960794 | 0.76 | FLT1 (0.42) | FLT1KDRPLAUPLGMAOB | |
| SCHEMBL18939141 | 0.75 | FLT1 (0.54) | FLT1KDRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | CEP170, AADAC, NAA50 | FLT1 3469/4885KDR 3855/4885PLAU 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.